Deepak Malhotra

I have few questions. First question is regarding the other income. I just wanted to understand the breakup of the same. I mean is it going to be a concurrent feature going forward since we have a bit of cash on the balance sheet, please?

And before I ask my second question, I obviously want to congratulate, I mean the management team for what you achieved. I think this is quite spectacular indeed. Now most of my questions have been kind of partially answered and just to rephrase, you talked of basically reinventing the business in terms of the growth strategy going forward?

Yes. Just to pick up on that. In terms of the way Revlimid has been such a staggering success, over the next 2, 3 years, I know it won't be possible to share in terms of the acquisition targets or what exactly you are looking at internally.